| (Values in U.S. Thousands) | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 | Jun, 2024 |
| Sales | 143,620 | 500 | 410 | 520 | 1,250 |
| Sales Growth | +28,624.00% | +21.95% | -21.15% | -58.40% | +150.00% |
| Net Income | 97,580 | -52,890 | -36,650 | -61,430 | -47,900 |
| Net Income Growth | +284.50% | -44.31% | +40.34% | -28.25% | +3.85% |
Igm Biosciences Inc (IGMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
IGM Biosciences Inc. is a biotechnology company. It engages in the research and development of engineered Immunoglobulin M antibodies for the treatment of cancer patients. The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM, which are in clinical stage. IGM Biosciences Inc. is based in Mountain View, California.
Fiscal Year End Date: 12/31